[
    [
        {
            "time": "",
            "original_text": "【天风医药】康泰生物：2019年业绩实现快速增长，进入大品种收获期",
            "features": {
                "keywords": [
                    "康泰生物",
                    "2019年",
                    "业绩",
                    "快速增长",
                    "大品种",
                    "收获期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【天风医药】康泰生物：2019年业绩实现快速增长，进入大品种收获期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "【民生医药|点评】康泰生物：业绩略超预期，四联苗驱动业绩增长,研发即将进入收获期",
            "features": {
                "keywords": [
                    "康泰生物",
                    "业绩",
                    "略超预期",
                    "四联苗",
                    "驱动",
                    "业绩增长",
                    "研发",
                    "收获期"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【民生医药|点评】康泰生物：业绩略超预期，四联苗驱动业绩增长,研发即将进入收获期",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "【国元医药】康泰生物2019业绩预告点评：利润端增速略超预期，期待后续新品上市",
            "features": {
                "keywords": [
                    "康泰生物",
                    "2019",
                    "业绩预告",
                    "利润端",
                    "增速",
                    "略超预期",
                    "新品",
                    "上市"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国元医药】康泰生物2019业绩预告点评：利润端增速略超预期，期待后续新品上市",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]